← Back to Browse

Zura Bio Limited

ZURA • Healthcare

Compare
1
Grade F
Compass

About Zura Bio Limited

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Current Price
$5.11
Market Cap
$409M

Quality Assessment

Zura Bio Limited is a high-risk healthcare company with a Compass Score of 1. Poor quality metrics and high risk. Not one for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Hold
Analysts
5
Price Target
🔒
Upside
🔒

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
🔒
EPS Beat Streak
🔒
Net Upgrades (180d)
🔒

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
🔒
Projected Revenue Growth
🔒

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.